|
|
Volumn 335, Issue 6066, 2012, Pages 282-283
|
|
Clinical trials: Experimental cancer therapies move to the front line
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
B RAF KINASE;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
NEW DRUG;
TRASTUZUMAB;
VEMURAFENIB;
CANCER;
CELL ORGANELLE;
DEVELOPMENTAL BIOLOGY;
DISEASE PREVALENCE;
ENZYME ACTIVITY;
EPIDEMIOLOGY;
EXPERIMENTAL STUDY;
GENE EXPRESSION;
GENOMICS;
TUMOR;
ADVANCED CANCER;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER DIAGNOSIS;
CANCER MORTALITY;
CANCER PATIENT;
CANCER RISK;
CANCER STAGING;
CANCER SURVIVAL;
CANCER THERAPY;
CLINICAL TRIAL (TOPIC);
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG SCREENING;
FOOD AND DRUG ADMINISTRATION;
GENE EXPRESSION;
HIGH RISK PATIENT;
HUMAN;
LUNG CANCER;
LYMPH NODE METASTASIS;
MELANOMA;
PRIORITY JOURNAL;
PROSTATE CANCER;
SCIENTIST;
SHORT SURVEY;
SKIN CANCER;
SQUAMOUS CELL CARCINOMA;
|
|
EID: 84856069770
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.335.6066.282 Document Type: Short Survey |
|
Times cited : (5)
|
|
References (0)
|
